Vivo Bio Tech Ltd.

Vivo Bio Tech Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 April 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 27 April 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 Apr 2026. This change is primarily driven by a shift in technical indicators, although the company continues to face challenges in financial performance and valuation metrics. The stock price rose 7.63% on the day following the upgrade, reflecting renewed investor interest amid mixed signals.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with the latest comprehensive analysis.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

For the fifth consecutive session, Vivo Bio Tech Ltd. has closed lower, slipping to a fresh 52-week low of Rs 21.9 on 30 Mar 2026. This decline comes amid a broader market downturn, but the stock’s underperformance is notably sharper than its sector peers.

Despite a broadly positive market environment, Vivo Bio Tech Ltd. has plunged to a fresh 52-week low of Rs 22.23 on 27 Mar 2026, extending its recent downtrend amid heightened volatility and sector underperformance.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Shares of Vivo Bio Tech Ltd. touched a fresh 52-week low of Rs.23 today, marking a significant decline amid persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial health and market positioning.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Vivo Bio Tech Ltd., a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.24.52 today, marking a significant decline amid persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial and market performance.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and technical outlook.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Vivo Bio Tech Ltd., a player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.25.2 today, marking a significant decline in its stock price amid a broader market environment showing mixed signals. The stock’s performance reflects ongoing pressures, with a notable underperformance relative to its sector and benchmark indices.

Vivo Bio Tech Ltd., a player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 19 Jan 2026. This revision reflects deteriorating technical indicators, stagnant financial trends, weak quality metrics, and a valuation that, while attractive, is overshadowed by the company’s faltering fundamentals and poor market performance relative to benchmarks like the Sensex.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 November 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Vivo Bio Tech . has reached a new 52-week low of Rs.25.21 today, marking a significant decline in its stock price amid broader sector pressures and company-specific performance factors. The stock has recorded a three-day consecutive fall, accumulating a near 10% loss over this period, underperforming the Pharmaceuticals & Biotechnology sector by 1.92% on the day.

Vivo Bio Tech . has reached a new 52-week low of Rs.25.21 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Vivo Bio Tech, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical performance. The stock’s recent assessment highlights a combination of subdued growth metrics, valuation appeal, and bearish technical signals, contributing to a shift in market perspective.